Table 1

Information of patients who suffered carcinoma development after sclerotherapy
Case Patient age(years)/sex Lesion location Primary lesion Duration of carcinoma development (months) Sclerosants used Total dose Reference
1 54.7 ± 6/M Esophagus Esophageal varices 12-30 Polidocanol 90-310 ml [3]
2 Unknown Esophagus Esophageal varices 24 Sodium morrhuate 10 ml [4]
3 Unknown Esophagus Esophageal varices 21 Ethanolamine oleate 45.5 ml [4]
4 52/M Esophagus Esophageal varices 36 Polidocanol 117 ml [5]
5 58.3 ± 5.0/Unknown Esophagus Esophageal varices 9-33 Ethanolamine oleate 51.0 ± 18.9 ml [6]
6 56/M Esophagus Esophageal varices 54 Ethanolamine oleate 70 ml [7]
7 Unknown Esophagus Esophageal varices 5-48 Sotradecol 30 ml [8]
8 47/F Kidney Simple renal cyst 36 Minocycline and Ethanol 200 mg [9]
9 65/F Tongue Venous malformation 65 Pingyangmycin and Sodium morrhuate 174 mg Present case

Chen et al.

Chen et al. Diagnostic Pathology 2013 8:182   doi:10.1186/1746-1596-8-182

Open Data